eGFR: What Your Number Changes About Your Treatment

What eGFR Actually Measures

EGFR is a calculated estimate of how many milliliters of blood your kidneys fully clear of creatinine per minute, normalized to a standard body surface area of 1.73 m². The CKD-EPI 2021 equation, which removed race as a variable, is now the preferred formula at most U.S. Laboratories and is endorsed by the National Kidney Foundation and the American Society of Nephrology. The full equation and validation data are published in the New England Journal of Medicine.

Why the formula change matters

The 2021 CKD-EPI revision produced systematically higher eGFR values for Black patients under the old race-adjusted model, meaning some people were previously assigned a worse kidney-function category than their creatinine alone justified. A 2021 validation study in NEJM (N=1,248 participants) confirmed the race-free equation reclassified approximately 23% of previously race-adjusted patients into a better CKD stage. See the validation data at PubMed. That reclassification can directly affect which drugs your prescriber considers safe.

How a single blood draw produces the number

The lab measures serum creatinine. Your age, sex assigned at birth, and body weight feed into the CKD-EPI formula alongside that creatinine value. Some labs also report cystatin C-based eGFR (eGFRcys) as a confirmatory value when creatinine may be unreliable, for example in patients with very low muscle mass or high protein intake. The KDIGO 2024 CKD Clinical Practice Guideline recommends using both creatinine and cystatin C when the eGFR is between 45 and 59 to confirm staging before making irreversible treatment decisions.

Normal eGFR Range and CKD Staging

An eGFR at or above 60 mL/min/1.73 m² is generally considered normal kidney function, though the presence of kidney damage markers (protein in urine, structural abnormality) can mean CKD even at higher values. The KDIGO framework divides kidney function into six G-stages. Full staging criteria appear in the KDIGO 2024 guideline.

KDIGO G-stage reference table

| G Stage | eGFR (mL/min/1.73 m²) | Description | |---------|----------------------|-------------| | G1 | 90 or higher | Normal or high | | G2 | 60-89 | Mildly reduced | | G3a | 45-59 | Mildly to moderately reduced | | G3b | 30-44 | Moderately to severely reduced | | G4 | 15-29 | Severely reduced | | G5 | Below 15 | Kidney failure |

G3a is the inflection point where most prescribing restrictions begin to stack. A patient who crosses from G2 to G3a may face metformin dose halving, SGLT-2 reassessment, and an annual nephrology referral discussion, all from a single lab result.

What "normal" really means at age 60+

EGFR declines about 1 mL/min/1.73 m² per year after age 40 as a normal aging process. An eGFR of 65 in a 72-year-old does not mean they are about to need dialysis. The National Institute of Diabetes and Digestive and Kidney Diseases notes that trajectory (is it stable or falling?) matters as much as the absolute number. A confirmed 5-point drop over 12 months warrants a workup even if the absolute value looks "acceptable."

Metformin and eGFR: The Thresholds That Change Everything

Metformin is the first-line oral agent for type 2 diabetes in nearly every major guideline, including the 2024 American Diabetes Association Standards of Care. Its safety in reduced kidney function depends entirely on eGFR, because lactic acidosis risk rises when the drug accumulates in patients who cannot clear it.

The three eGFR zones for metformin

eGFR 45 or above: Full standard dosing. Up to 2,550 mg/day is acceptable. No additional monitoring beyond routine diabetes care is required for renal reasons alone.

eGFR 30-44: Caution zone. The FDA-revised metformin labeling permits continued use but recommends reassessing frequently and not starting metformin for the first time in this range in some clinical contexts. Dose reductions to 1,000 mg/day or less are common practice.

eGFR below 30: Contraindicated. The same FDA label is explicit. Stop metformin and transition to an alternative. Many patients at this stage move to a GLP-1 receptor agonist, an SGLT-2 inhibitor within its approved renal range, or insulin.

GLP-1 Receptor Agonists and Kidney Function

GLP-1 receptor agonists have become the fastest-growing drug class in metabolic medicine, and their renal profiles differ meaningfully from metformin. This matters for the large overlap between obesity, type 2 diabetes, and CKD.

Semaglutide renal profile

The FDA label for semaglutide (Ozempic and Wegovy) does not require dose adjustment for any level of kidney impairment, including patients on dialysis. That permissive labeling is backed by the FLOW trial, published in NEJM in 2024 (N=3,533 patients with type 2 diabetes and CKD), which showed semaglutide 1.0 mg weekly reduced the risk of a major kidney-disease event by 24% versus placebo (hazard ratio 0.76, 95% CI 0.66-0.88, P<0.001). Full FLOW trial results at NEJM.

Liraglutide and dulaglutide

Liraglutide (Victoza/Saxenda) should be used with caution below eGFR 15 based on limited data, though no formal contraindication exists in the FDA label. Dulaglutide (Trulicity) similarly carries no renal dose adjustment requirement per its label. Both drugs show a class-level trend toward reduced albuminuria, which the ADA 2024 Standards of Care now recognizes as a reason to prefer GLP-1 agonists in patients with diabetic kidney disease.

GI side effects and dehydration risk

One underappreciated renal concern with GLP-1 agonists is nausea-driven volume depletion. In patients already at G3b or G4, a one-week episode of vomiting can precipitate an acute-on-chronic kidney injury. Clinicians managing GLP-1 starts in CKD patients often check a repeat creatinine 4-6 weeks after initiation, particularly if the patient reports significant nausea.

SGLT-2 Inhibitors: The eGFR Floor Is Moving

SGLT-2 inhibitors block glucose reabsorption in the proximal tubule, and that mechanism requires functioning nephrons. For years, the cutoff for glycemic use was eGFR 45. That floor has shifted based on outcomes data.

Empagliflozin (Jardiance) cardio-renal extension

The EMPA-KIDNEY trial (NEJM, 2023, N=6,609) showed empagliflozin 10 mg daily reduced progression of kidney disease or cardiovascular death by 28% (HR 0.72, 95% CI 0.64-0.82, P<0.001) in patients with eGFR as low as 20 mL/min/1.73 m². EMPA-KIDNEY full results at NEJM. The FDA updated Jardiance labeling in 2023 to reflect cardiovascular and renal protection down to eGFR 20, though glycemic lowering at that level is minimal.

Dapagliflozin (Farxiga) CKD label

The DAPA-CKD trial (NEJM, 2020, N=4,304) demonstrated that dapagliflozin 10 mg daily reduced a composite of 50% eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51-0.72, P<0.001) in CKD patients regardless of diabetes status. DAPA-CKD data at NEJM. The FDA approved dapagliflozin for CKD in 2021, with use permitted down to eGFR 25.

The acute eGFR dip after starting an SGLT-2

Within 2-4 weeks of starting an SGLT-2 inhibitor, eGFR typically drops 3-5 mL/min/1.73 m² due to hemodynamic effects on glomerular filtration pressure. This is expected and does not indicate drug toxicity. The KDIGO 2022 Diabetes Management in CKD guideline specifically advises clinicians not to discontinue the drug based on this initial dip alone, provided the drop is less than 30% from baseline and stabilizes.

Testosterone Replacement Therapy and eGFR

Testosterone replacement therapy (TRT) does not require renal dose adjustment in any FDA-approved label. The kidneys clear very little free testosterone. Still, eGFR status shapes two monitoring decisions.

Erythrocytosis and hematocrit monitoring

Testosterone stimulates erythropoiesis. In CKD G3b-G5, endogenous erythropoietin is already dysregulated, and adding exogenous testosterone can push hematocrit above 54% with less provocation than in patients with normal kidney function. The Endocrine Society 2018 Testosterone Therapy Guidelines recommend checking hematocrit at 3-6 months after initiation and then annually. In patients with eGFR below 45, a more conservative target of hematocrit below 50% is reasonable practice, and some clinicians shorten that monitoring interval to every 3 months.

Fluid retention and blood pressure

Testosterone can cause sodium and water retention. In patients with reduced kidney function, that retention is harder to compensate for. Blood pressure monitoring at every visit is standard when combining TRT with stage G3 or worse CKD. The dose or formulation may need adjustment if systolic blood pressure rises above 130 mmHg, given that KDIGO 2024 now recommends a blood pressure target below 120/80 in most CKD patients based on the SPRINT trial data.

How eGFR Affects Contrast Dye and Imaging Decisions

This section falls outside direct prescribing but affects patients frequently. Iodinated contrast used in CT scans can cause contrast-induced nephropathy, though modern evidence suggests the risk is lower than historically assumed. The American College of Radiology Manual on Contrast Media (2023) currently states that routine contrast is acceptable above eGFR 30, with case-by-case judgment between eGFR 15 and 30, and that prophylactic IV hydration is the primary mitigation strategy, not contrast avoidance.

Gadolinium-based MRI contrast is a separate issue. Gadolinium can cause nephrogenic systemic fibrosis in patients with eGFR below 30. Most radiology departments will not administer group I gadolinium agents below that threshold without a formal risk-benefit discussion documented in the chart.

How to Raise a Low eGFR (or at Least Slow Its Decline)

"Raising" eGFR is possible in some situations. Reversing acute contributors, like dehydration, NSAIDs, or an active infection, can restore eGFR toward baseline within days to weeks. Genuine recovery of chronically lost nephrons is not possible, but slowing the rate of further loss is achievable and clinically meaningful.

Blood pressure control

The most consistent modifiable factor in CKD progression is blood pressure. ACE inhibitors and ARBs reduce intraglomerular pressure and are first-line for CKD with albuminuria. The AASK trial (N=1,094) showed that ramipril reduced the risk of GFR decline, ESRD, or death by 22% compared to amlodipine in hypertensive CKD. Target blood pressure is now below 120/80 per KDIGO 2024.

Protein in the urine as a treatment target

Albuminuria, not just eGFR, drives prescribing. A urine albumin-to-creatinine ratio (uACR) above 300 mg/g combined with eGFR in the G3 range puts a patient in a high-risk category where both an ACE inhibitor/ARB and an SGLT-2 inhibitor are recommended concurrently by the ADA 2024 Standards of Care. Getting albuminuria below 30 mg/g is considered a secondary treatment target alongside eGFR stabilization.

Dietary protein and sodium

The KDIGO 2024 guideline recommends dietary protein intake of 0.6-0.8 g/kg/day for non-dialysis CKD patients not at nutritional risk, and sodium intake below 2 g/day. High-protein diets, which are common in weight-loss and TRT contexts, may accelerate hyperfiltration injury in patients already at G3 or below. This is a direct interaction between lifestyle choices popular in the telehealth-metabolic space and renal outcomes.

The HealthRX eGFR-to-Rx Decision Framework

The table below maps eGFR stage to the five drug classes most relevant to HealthRX patients.

| eGFR (mL/min/1.73 m²) | Metformin | GLP-1 Agonist | SGLT-2 Inhibitor | TRT | ACE/ARB | |----------------------|-----------|---------------|------------------|-----|---------| | 60 or above | Full dose | Full dose | Full dose | Full dose, standard monitoring | Use if albuminuria present | | 45-59 | Full dose, monitor q6mo | Full dose | Full dose, glycemic benefit present | Full dose, hematocrit q6mo | First-line if albuminuria | | 30-44 | Reduce dose; avoid new starts | Full dose | Cardiorenal only; glycemic benefit minimal | Full dose, hematocrit q3-6mo | First-line; watch K+ | | 15-29 | Contraindicated | Full dose (semaglutide confirmed) | Empagliflozin/dapagliflozin for cardiorenal benefit | Full dose, shortened monitoring | First-line; watch K+ | | Below 15 / dialysis | Contraindicated | Use with caution; semaglutide data exist | Generally stopped; specialist guidance | Full dose, close monitoring | Specialist-directed |

What a High eGFR Means

An eGFR above 120 mL/min/1.73 m² is labeled G1 but may indicate hyperfiltration, a state where glomeruli are working under excessive pressure. Early diabetic nephropathy often presents with a paradoxically high eGFR before progressive damage reduces it. The ADA 2024 Standards of Care recommends annual uACR screening in all patients with type 2 diabetes regardless of eGFR level, precisely because a "normal" or elevated eGFR can coexist with early kidney damage detectable only by albuminuria.

A genuinely elevated eGFR in a young, well-hydrated patient with no metabolic disease requires no intervention. It does not trigger any prescribing changes. The clinical concern is exclusively whether it represents early hyperfiltration in a patient with diabetes, hypertension, or obesity, because that group will experience eGFR decline over the following decade if the underlying driver is not treated.

How Often Your eGFR Should Be Rechecked

Monitoring frequency depends on your current stage and clinical context. The KDIGO 2024 framework assigns a "heat map" of recommended monitoring frequency by stage and albuminuria category.

Standard rechecking intervals

Patients with eGFR above 60 and no albuminuria need eGFR checked once per year as part of routine metabolic labs. Patients at G3a (45-59) need it every 6 months. Patients at G3b (30-44) need it every 3-6 months. At G4 (15-29), every 3 months is standard.

Any time a new nephrotoxic drug is added (NSAIDs, aminoglycosides, high-dose ACE inhibitor in a patient already on an SGLT-2), a repeat creatinine at 1-4 weeks after initiation is appropriate clinical practice. The KDIGO 2024 guideline also specifies that acute illness with fever, vomiting, or diarrhea is an indication to recheck eGFR and consider temporarily holding renally cleared drugs, a principle sometimes called "sick-day rules."